28th fda catalyst
Komen:
Fundamentals are very poor, last submission to FDA failed making the stakes very high for long term investors, could start to push bearish under the support level.
Komen:
Either that or big corps will interfere putting funds in for a bullish look grabbing the attention of traders to push upwards.